
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
SubjectWell announced that it has developed a growing patient registry of individuals in the U.S. interested in participating in clinical trials for a COVID-19 vaccine as these trials become more widely available. 10,000 people from SubjectWell’s patient network have already opted into the list, with approximately 70,000 individuals expected to register by the end of May. Researchers will have access to interested individuals who could randomize for various types of trials, whether they are healthy volunteers with no previous exposure to COVID-19, currently sick with the virus, or who have recovered.
For more information, click






